MTOR and acute lymphoblastic leukemia: In vitro experiments performed on T-ALL cells and steroid-resistant patient-originated T-ALL xenograft cells showed that the mTOR inhibitor everolimus augmented ROS concentrations, increased lipid peroxidation, and stimulated the ROS-regulated transcription factor NRF2.